Dr. Kratika Daniel
@oui.in
Professor
Facutly of Pharmacy, Oriental university, Indore MP
RESEARCH, TEACHING, or OTHER INTERESTS
Pharmaceutical Science, Chemistry, Drug Discovery, General Pharmacology, Toxicology and Pharmaceutics
Scopus Publications
Scopus Publications
Kratika Daniel, Vivek Daniel, Charanjeet Singh, Anil K Gupta, and Yashwant Daniel
Dr. Yashwant Research Labs Pvt. Ltd.
Introduction: Commercially available oral hypoglycemic drugs are known to be potential alpha-amylase inhibitors that reduce postprandial hyperglycemia. Natural drugs are nowadays very popular in the treatment of diabetes. Aim and Objectives: This study investigated in-vitro alpha-amylase inhibition of Momordica charantia and Emblica officinalis and studied the interaction between active phytoconstituents and alpha-amylase enzyme. Method: Active constituents of both fruits were identified, docking studies were performed using Autodock Vina, and interactions were studied using PyMOL and Discovery Studio. The alpha-amylase inhibitory potentials of the fresh juice were investigated at the concentration of the fresh juice with alpha amylase enzyme and starch solution at 565 nm was observed. Result: With the docking studies, it was observed that momoridicin I and II showed better interaction with alpha-amylase enzyme (PDB ID: 1B2Y) and showed binding energies at -8.2 and -8.4 Kcal/mol, respectively. The fresh juice of both fruits showed the most effective alpha-amylase inhibition and IC50 values found at 440 and 312 μL/mL, respectively. Summary and Conclusion: The attempt to study in-silico docking studies and in-vitro alpha-amylase enzyme inhibition were successfully performed. Comparatively, M. charantia showed more enzyme inhibition at low concentrations.
Priyanka . Rathore, Kratika . Daniel, Vivek . Daniel, Charanjeet . Singh, Yashwant . ., and Anil K. Gupta
Dr. Yashwant Research Labs Pvt. Ltd.
Gokshura tablet is an ayurvedic formulation with gokhru (Tribulus terrestris) as best fixing recommended for building vitality levels. It enhances life, sexual want and drive. Pushyanug churna is an ayurvedic polyherbal formulation, hence this seems essential to explain the material institutionalization, various bioactive markers, blends exhibit in the polyherbal ayurveda compositions such as pushyanug churna. Point of the exhibit effort has been to create what’s more, approve a high-performance thin layer chromatography (HPTLC) strategy for assurance of diosgenin present in gokshura tablet. Mangiferin and chlorogenic acid are present in pushyanug churna. Diosgenin, a biomarker chemical found in gokshura tablets, and mangiferin, a biomarker compound found in pushyanug churna, were standardized using recently developed easy and accurate HPTLC procedures. Pre-coated silica gel 60-F254 was employed at the stationary phase and a mixture of toluene, ethyl acetate, and formic acid (in the proportions 5:4:1) was employed for the mobile phase in the development methodology for diosgenin. In the mobile phase, mangiferin, ethyl acetate and methanol were added in a ratio of 40:60 v/v were utilized. In the chlorogenic acid mobile phase, ethyl acetate:formic acid:acetic acid:water (10:1.1:1.1:2.6 v/v). It was determined that the Rf value of the marker chemical was 0.77 (diosgenin) in gokhsura tablet and 0.23 mangiferin, 0.75 chlorogenic acid in pushyanug churna. For bioactive marker chemicals found in in-house and commercially available formulations, the developed HPTLC approach has shown to be straightforward, sensitive, specific, and dependable.
Bharatee P. Chaudhari and Kratika Daniel
A and V Publications
A simple, exceptionally cost-effective, extremely accurate, quite precise and highly reproducible analytical method was developed and validated for simultaneous estimation of Diacerein and Aceclofenac in bulk and Pharmaceutical formulation. The new Ultra Performance Liquid Chromatography technique was developed. Method- The separation has been done on column ACQUITY UPLC BEH Shield C18 (50 x 2.1mm), 1.7µm (40°C temperature). The mobile phase contained Buffer and Acetonitrile (Buffer: ACN) (55:45 V/V).. The flow rate was set at 0.4ml/min, and detected at 268nm with PDA detector. Mobile phase was sonicated for 15 min. before use. 5μl of samples of standard stock solution and tablet solution were injected. Different trials were performed to separate diacerein and aceclofenac. The total run time of the detection was 4 min. The developed method was validated against different validation parameters. Results - The retention times were obtained at 1.762min. and 2.891 min. for Diacerein and Aceclofenac respectively. Accuracy study was observed in the range of 100.33% to 101.67% with less than 2% RSD. LOQ was found to be 2.98μg/ml and 5.9041μg/ml. similarly LOD was found to be 0.9841μg/ml and 1.9467μg/ml. for Diacerein and Aceclofenac respectively. Precision %RSD for intraday and interday were found to be 0.19 and 0.18 for Diacerein , 0.44 and 0.16 for Aceclofenac respectively. Linearity was found in the range of 2.5-17.5μg/ml and 5-35μg/ml for Diacerein and Aceclofenac respectively. The method was found robust by deliberate changes in the flow rate, ratio of mobile phase and detection wavelength. Conclusion-The method was found to be satisfactory and can be used successfully for determination of Diacerein and Aceclofenac simultaneously in bulk and pharmaceutical dosage form.
Ajinkya Chavan, Kratika Daniel, and Ansar M. Patel
Bentham Science Publishers Ltd.
Background: Diabetes has a large death toll worldwide, particularly as it falls into the ten leading causes of death. Type 2 diabetes mellitus (T2DM) occurs as the body becomes resistant to insulin and sugar accumulates in the blood. It has been observed that dipeptidyl peptidase-IV (DPP-IV) inhibitors and glucokinase activators are known therapeutic agents to treat T2DM. Among the possible medicinal plants, Gymnema sylvestre (GyS) belongs to the Apocynaceae family and is traditionally used for the treatment of different diseases. This plant is also known as “Gurmur” because it has a sugarreducing ability. GyS is known to be one of the main botanicals for the treatment of diabetes. Objective: Considering the studies described above, we have tried to investigate the natural DPP-IV inhibitors and potent glucokinase activators from the phytoconstituents of GyS. New drug candidates from the medicinal plant GyS have been reported as potent DPP-IV inhibitors and glucokinase activators. Methods: As a preliminary investigation, we have studied the effectiveness of phytoconstituents of GyS in T2DM through molecular docking as a proof of concept of synthesizing silver nanoparticles (for the treatment of T2DM) using an extract of this plant. Results: The present investigative research shows that the recognized compounds included in the present analysis have important values in the treatment of diabetes mellitus. The nine compounds selected are evaluated on the basis of DPP-IV and glucokinase enzyme binding energy values and their drug properties. Except for quercitol, all the selected compounds have exhibited much more potent glucokinase activation potential than their native ligands. Gymnemasin A, lupeol, gymnemoside A, gymnemasaponin V, and gymnemic acid I have shown excellent DPP-IV inhibitory potential. Conclusion: We aimed to synthesize the silver nanoparticles from the leaf extract of GyS for the treatment of T2DM. As a preliminary investigation, we have studied the effectiveness of phytoconstituents of GyS in T2DM through molecular docking as proof of synthesizing silver nanoparticles (for the treatment of T2DM) using an extract of this plant. As a result of the present investigation, it has been concluded that these compounds can be used to treat T2DM, and hence, in the future, we can synthesize the silver nanoparticles from the GyS extract for the treatment of T2DM.
Sadanand Mallurwar, Kratika Daniel, and Mahesh Bhat
Oriental Scientific Publishing Company
Purpose: The primary motive of this study was to examine advantages of allometry scaling strategies for correct prediction of pharmacokinetics of Baricitinib in human from preclinical species. Baricitinib is basically Janus kinase (JAK) inhibitor used for the treatment of rheumatoid arthritis. Currently approved by FDA in combination with remdesivir for treatment of COVID-19 hospitalized patient. Methods: The literature published pharmacokinetic parameters (Cl and Vd) of preclinical species (Rat, Dog and monkey) were utilized for the allometry scaling of Baricitinib. The connection among the primary pharmacokinetic parameters [Volume of distribution (Vd) and clearance (Cl)] and body weight (BW) were studied across three preclinical species, we used the double logarithmic plots for prediction of the human pharmacokinetic parameters i.e. Cl and Vd with use of simple allometry and with additional correction factors for better prediction. The dose extrapolation of baricitinib was carried out by FDA guidelines. Results: By application of the allometric scaling methods and principles correlation was found to be satisfactory for the prediction of intravenous human Cl and Vd for baricitinib. The volume of distribution (Vd) predicted by simple allometry (65.3 L) was found to be in agreement with the reported value (75.5 L); clearance (Cl) prediction by simple allometry was found to be at least 1.06 -closer to the reported value (245 mL/min); CF were used to predict the clearance. Both brain weight (B.W) and maximum life span potential (MLP) predicted the Cl with 0.52- and 0.61 -fold difference. The application of monkey liver blood flow predicted Cl with 0.81 fold which was also in close agreement with reported value. The Cl prediction was also extrapolated using LBF (Liver blood flow) method and observed that the higher species (Dog and Monkey) have predicted Cl with better accuracy than rat. Conclusions: Overall, the simple allometry (SA), monkey liver blood flow (MLBF) and application of liver blood flow (LBF) methods showed excellent correlation with human. The time vs. plasma concentration simulated graph also showed the similar closeness with human profile. The inclusion of plasma protein binding factor didn’t improve the prediction accuracy. The FIH dose extrapolation were showed that PK guided approach and exponent for BSA based approach was found closer to actual human dose of 4.0 mg/Kg.
Anuja Kolsure, Kratika Daniel, and Mahesh Bhat
A and V Publications
Budesonide is a potent glucocorticoid with a high local anti-inflammatory effect and low systemic bioavailability. The inhaled form is used in the long-term management of asthma and chronic obstructive pulmonary disease. Several analytical methods including UV, HPLC, LC-MS techniques has been developed for Budesonide alone and in combination with others. Methods indicating HPLC bioanalytical method, stability indicating HPLC method, ion pairing chromatographic method and chemometrics assisted HPLC methods are also described for Budesonide. For qualitative and quantitative estimation of Budesonide these analytical methods can be used. The following study describes reported analytical methods of Budesonide.